Frequency of Antihypertensive Drug Classes and Single‐Pill Combinations in Obese Patients: An 8‐Year Retrospective Study
The Journal of Clinical Hypertension · 2025
DOI: 10.1111/jch.70143 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Clinical Hypertension, 2025. Verfasst von Beata Moczulska und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology and Internal Medicine, School of Medicine, University of Warmia and Mazury in Olsztyn, Olsztyn, Poland. Hauptthemen laut MEDLINE: Hypertension, Antihypertensive Agents, Obesity. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Statutory Fund of the School of Medicine, Collegium Medicum, University of Warmia and Mazury in Olsztyn.
Abstract (Originalsprache)
Obesity is a major contributor to the development and progression of hypertension, and its coexistence significantly increases cardiovascular risk. Although numerous guidelines exist for the management of arterial hypertension, none are dedicated specifically to obese patients, despite their increasing prevalence. Since 2018, both European and Polish guidelines have recommended the use of single‐pill combinations (SPCs) at every stage of treatment. This retrospective study aimed to evaluate antihypertensive treatment patterns over the past eight years among obese patients. This analysis was restricted to obese patients with hypertension to explore prescribing patterns in a subgroup with unique pathophysiological features and high cardiovascular risk, for which specific therapeutic recommendations remain limited. The study cohort was limited to obese patients hospitalized for preoperative assessment prior to planned bariatric surgery. We analyzed medical records of 233 obese hypertensive patients divided into two cohorts: those diagnosed before 2020 and those diagnosed in 2020 or later. We observed a significant increase in the use of three or more antihypertensive drugs and a rise in the prescription of beta‐blockers and angiotensin receptor blockers after 2020. Despite these changes, the use of SPCs remained low: two‐drug SPCs were used in 35.6% of patients, and three‐drug SPCs in only 11.2%, with no significant increase in their use over time. Additionally, SGLT2 inhibitors were introduced into therapy after 2020. Our findings highlight the discrepancy between clinical guidelines and real‐world prescribing habits. Improved adherence to treatment recommendations may enhance therapeutic outcomes and medication adherence in this high‐risk group.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiology and Internal Medicine, School of Medicine, University of Warmia and Mazury in Olsztyn, Olsztyn, Poland.
- Department of Psychology and Sociology of Health and Public Health, School of Public Health, University of Warmia and Mazury in Olsztyn, Olsztyn, Poland.
- Department of Human Physiology and Pathophysiology, School of Medicine, University of Warmia and Mazury in Olsztyn, Olsztyn, Poland.
ORCID-Profile: Beata Moczulska, Karolina Osowiecka, Leszek Gromadziński, Marta Majewska
Förderung
- Statutory Fund of the School of Medicine, Collegium Medicum, University of Warmia and Mazury in Olsztyn
Zitieren
APA
Moczulska, B., Osowiecka, K., Gromadziński, L., & Majewska, M. (2025). Frequency of Antihypertensive Drug Classes and Single‐Pill Combinations in Obese Patients: An 8‐Year Retrospective Study. The Journal of Clinical Hypertension. https://doi.org/10.1111/jch.70143
Vancouver
Moczulska B, Osowiecka K, Gromadziński L, Majewska M. Frequency of Antihypertensive Drug Classes and Single‐Pill Combinations in Obese Patients: An 8‐Year Retrospective Study. The Journal of Clinical Hypertension. 2025. doi:10.1111/jch.70143
BibTeX
@article{Moczulska2025,
author = {Moczulska, Beata and Osowiecka, Karolina and Gromadziński, Leszek and Majewska, Marta},
title = {Frequency of Antihypertensive Drug Classes and Single‐Pill Combinations in Obese Patients: An 8‐Year Retrospective Study},
journal = {The Journal of Clinical Hypertension},
year = {2025},
doi = {10.1111/jch.70143}
}
EUVIMED